Lung Cancer Diagnostics Market to Reach US$ 26.3 Bn by End of 2031, as per TMR Report

Technological advancements in diagnostic approaches and cancer therapy are projected to propel the industry during the forecast period


Wilmington, Delaware, United States, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.The global Lung Cancer Diagnostics Market is likely to expand at a CAGR of 7.3% between 2023 and 2031. An increase in cases of lung cancer globally is expected to boost market growth during the forecast period. A rise in awareness about the availability of lung cancer treatment and a surge in success rates are projected to bolster market expansion during the forecast period.

The surge in awareness about the significance of cancer diagnostics is driving the adoption of lung cancer diagnostics in developing and developed countries. Added advantages of early and accurate diagnostics are anticipated to augment industry growth during the forecast period. Furthermore, the advent and rise in popularity of biomarkers as a non-invasive diagnostic method is projected to present lucrative business opportunities in the lung cancer diagnostics market during the forecast period.

According to the TMR report, the global lung cancer diagnostics market is likely to reach US$ 26.3 Bn by the end of 2031. The rise in lung cancer cases globally and the increase in awareness about the availability of cancer therapy are boosting market growth.

Request to Sample PDF of this Strategic Report (Use Corporate Mail ID for Top Priority):
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74159

Key Findings of Study

  • Increase in Prevalence of Lung Cancer: Increase in the prevalence of lung cancer among people in both developed and developing countries is augmenting the global lung cancer diagnostics market. Advancements in diagnostics and the increase in the adoption of the latest therapeutic and diagnostic approaches to various cancer types are projected to accelerate industry growth in the next few years. The surge in the adoption of accurate and effective diagnostic testing for cancer is likely to drive the market in the near future.
  • Rise in Popularity of CT and PET Scans: The increase in popularity of imaging technology and non-invasive diagnostic methods, such as PET scans and CT scans, for detecting the presence of cancer cells in the body is fuelling market expansion

Key Drivers

  • The rise in the prevalence of lung cancer coupled with the advent of accurate imaging techniques for diagnostics
  • Increase in adoption of innovative biomarkers for lung cancer treatment
  • Surge in advancement in imaging technology and rise in adoption of PET scans for diagnostic treatment

Buy this Premium Research Report | Immediate Delivery Available:
https://www.transparencymarketresearch.com/checkout.php?rep_id=74159&ltype=S

Regional Growth Dynamics

  • Europe held the dominant market share in 2021. The trend is anticipated to continue during the forecast period due to the rise in cases of lung cancer. The availability of advanced medical infrastructure & facilities and the presence of leading players are expected to propel the market in the region in the next few years.
  • North America is likely to account for the second-largest market share during the forecast period. An increase in cases of lung cancer and advanced medical facilities for cancer treatment is projected to bolster market development in the next few years.

Key Players

Prominent players in the global lung cancer diagnostics market are

  • Thermo Fisher Scientific, Inc.,
  • Biodesix,
  • Quest Diagnostics Incorporated,
  • Paige AI,
  • Oncocyte Corporation,
  • Danaher,
  • Boditech Med Inc.,
  • F. Hoffmann-La Roche Ltd.,
  • Amoy Diagnostics Co.,
  • QIAGEN,
  • Abbott,
  • Illumina, and Bio-Rad Laboratories.

Ask for References:
https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=74159

Lung Cancer Diagnostics Market Segmentation:

Diagnostic Test

  • Imaging Tests
  • Pulmonary Function Tests
  • Lung Tissue Analysis
  • Others

Cancer Type

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

End-User

  • Hospitals
  • Clinics
  • Diagnostic Centers

Regions

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Countries

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • GCC Countries
  • South Africa
  • Brazil
  • Mexico

Related Healthcare Reports

About Transparency Market Research

Transparency Market Research, a global market research company registered in Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Websitehttps://www.transparencymarketresearch.com
Bloghttps://tmrblog.com
Email: sales@transparencymarketresearch.com